Related content

Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy

By Bellone S.   Palmieri M.   Gokden M.   Joshua J.   Roman J.J.   Pecorelli S.   Cannon M.J.   Santin A.D.  

Gynecologic Oncology, Vol. 91, Iss. 1, 2003-10 ,pp. : 231-240

Elsevier

Access to resources Recommend Favorite

S-Phase Fraction, p53, and HER-2/neu Status as Predictors of Nodal Metastasis in Early Vulvar Cancer

By Gordinier M.E.   Steinhoff M.M.   Hogan J.W.   Peipert J.F.   Gajewski W.H.   Falkenberry S.S.   Granai C.O.  

Gynecologic Oncology, Vol. 67, Iss. 2, 1997-11 ,pp. : 200-202

Elsevier

Access to resources Recommend Favorite

Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma

By Bermont L.  

Breast Cancer Research and Treatment, Vol. 63, Iss. 2, 2000-09 ,pp. : 163-169

Springer Publishing Company

Access to resources Recommend Favorite

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy

By Baxevanis Constantin   Sotiropoulou Panagiota   Sotiriadou Nectaria   Papamichail Michael  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 3, 2004-03 ,pp. : 166-175

Springer Publishing Company

Access to resources Recommend Favorite

Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age

By Li Christopher  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 579-587

Springer Publishing Company

Access to resources Recommend Favorite